Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature

In silico analysis of the immunological landscape of pituitary adenomas

(2020) Jacky T. Yeung et al.   JOURNAL OF NEURO-ONCOLOGY

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

(2019) Celeste Lebbé et al.   JOURNAL OF CLINICAL ONCOLOGY

The Intersection between Tumor Angiogenesis and Immune Suppression

(2019) Osama E. Rahma et al.   CLINICAL CANCER RESEARCH

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis

(2019) Lihu Gu et al.   BMC CANCER

Immune checkpoint inhibitors: The linchpins of modern immunotherapy

(2019) Breelyn A. Wilky   IMMUNOLOGICAL REVIEWS

Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab

(2019) Mario Caccese et al.   ANTI-CANCER DRUGS

Aggressive prolactinomas: how to manage?

(2019) Hélène Lasolle et al.   Pituitary

A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal

(2019) C. Villa et al.   VIRCHOWS ARCHIV

The Microenvironment of Pituitary Tumors—Biological and Therapeutic Implications

(2019) Mirela Diana Ilie et al.   Cancers

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016

(2018) Ann McCormack et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy

(2018) Peng-fei Wang et al.   JOURNAL OF NEURO-ONCOLOGY

Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas

(2018) Hou-Shi Ma et al.   MEDICAL SCIENCE MONITOR

Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab

(2018) Andrew L Lin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

French Endocrine Society Guidance on endocrine side effects of immunotherapy

(2018) F Castinetti et al.   ENDOCRINE-RELATED CANCER

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal

(2017) S L Asa et al.   ENDOCRINE-RELATED CANCER

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

(2017) Hélène Lasolle et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

(2017) Gerald Raverot et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

(2017) Hans J. Hammers et al.   JOURNAL OF CLINICAL ONCOLOGY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors

(2016) Yu Mei et al.   Oncotarget

Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas

(2015) Jian-Qiang Lu et al.   ENDOCRINE PATHOLOGY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION